197 related articles for article (PubMed ID: 14690098)
1. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam.
Weber EW; Slappendel R; Durieux ME; Dirksen R; van der Heide H; Spruit M
Eur J Anaesthesiol; 2003 Dec; 20(12):963-6. PubMed ID: 14690098
[TBL] [Abstract][Full Text] [Related]
2. Effect of selective vs. non-selective cyclo-oxygenase inhibitors on fetal membrane prostaglandin synthesis.
Sawdy R; Pan H; Sullivan M; Bennett P
J Obstet Gynaecol; 2003 May; 23(3):239-43. PubMed ID: 12850850
[TBL] [Abstract][Full Text] [Related]
3. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.
Blain H; Boileau C; Lapicque F; Nédélec E; Loeuille D; Guillaume C; Gaucher A; Jeandel C; Netter P; Jouzeau JY
Br J Clin Pharmacol; 2002 Mar; 53(3):255-65. PubMed ID: 11874389
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
[TBL] [Abstract][Full Text] [Related]
6. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers.
de Meijer A; Vollaard H; de Metz M; Verbruggen B; Thomas C; Novakova I
Clin Pharmacol Ther; 1999 Oct; 66(4):425-30. PubMed ID: 10546927
[TBL] [Abstract][Full Text] [Related]
7. Ischaemic colitis in a patient taking meloxicam.
Garcia B; Ramaholimihaso F; Diebold MD; Cadiot G; Thiéfin G
Lancet; 2001 Mar; 357(9257):690. PubMed ID: 11247558
[TBL] [Abstract][Full Text] [Related]
8. The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa.
Tavares IA
Aliment Pharmacol Ther; 2000 Jun; 14(6):795-9. PubMed ID: 10848664
[TBL] [Abstract][Full Text] [Related]
9. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers.
Stichtenoth DO; Wagner B; Frölich JC
J Investig Med; 1997 Feb; 45(2):44-9. PubMed ID: 9084574
[TBL] [Abstract][Full Text] [Related]
10. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
Walker MC; Kurumbail RG; Kiefer JR; Moreland KT; Koboldt CM; Isakson PC; Seibert K; Gierse JK
Biochem J; 2001 Aug; 357(Pt 3):709-18. PubMed ID: 11463341
[TBL] [Abstract][Full Text] [Related]
11. The effects of non-steroidal anti-inflammatory compounds on human myometrial contractility.
Sawdy RJ; Sullivan MH; Bennett PR
Eur J Obstet Gynecol Reprod Biol; 2003 Jul; 109(1):33-40. PubMed ID: 12818440
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
13. [Therapy with preferential and specific COX-2 inhibitors].
Stichtenoth DO; Frölich JC
Internist (Berl); 2001 Mar; 42(3):421-6. PubMed ID: 11277028
[No Abstract] [Full Text] [Related]
14. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
15. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
Tsubouchi Y; Sano H; Yamada R; Hashiramoto A; Kohno M; Kusaka Y; Kondo M
Eur J Pharmacol; 2000 May; 395(3):255-63. PubMed ID: 10812057
[TBL] [Abstract][Full Text] [Related]
16. Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers.
Stichtenoth DO; Wagner B; Frölich JC
J Investig Med; 1998 Aug; 46(6):290-6. PubMed ID: 9737091
[TBL] [Abstract][Full Text] [Related]
17. Central antinociceptive effects of meloxicam on rat spinal cord in vitro.
Lopez-Garcia JA; Laird JM
Neuroreport; 1998 Mar; 9(4):647-51. PubMed ID: 9559932
[TBL] [Abstract][Full Text] [Related]
18. Meloxicam and indomethacin activity on human matrix metalloproteinases in synovial fluid.
Barracchini A; Franceschini N; Minisola G; Pantaleoni GC; Di Giulio AD; Oratore A; Amicosante G
Ann N Y Acad Sci; 1999 Jun; 878():665-6. PubMed ID: 10415802
[No Abstract] [Full Text] [Related]
19. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
20. Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles.
Fenner H
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):28-33. PubMed ID: 9219317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
